References

russjcardiol

Российский кардиологический журнал

Russian Journal of Cardiology

1560-40712618-7620

«SILICEA-POLIGRAF» LLC

10.15829/1560-4071-2023-5485

WESQHI

russjcardiol-5485

Research Article

КЛИНИКА И ФАРМАКОТЕРАПИЯ. ОБЗОР ЛИТЕРАТУРЫ

CLINIC AND PHARMACOTHERAPY. LITERATURE REVIEW

Статинотерапия в режиме умеренной интенсивности. Вопросы эффективности и безопасности

Moderate-intensity statin therapy. Efficacy and safety issues

https://orcid.org/0000-0002-5328-0910

Гоголашвили

Н. Г.

Gogolashvili

N. G.

Красноярск

Krasnoyarsk

gng1963@mail.ru

НИИ медицинских проблем Севера — обособленное подразделение ФИЦ КНЦ СО РАН; ФГБОУ ВО КрасГМУ им. проф. Ф.В. Войно-Ясенецкого Минздрава РоссииРоссияResearch Institute of Medical Problems of the North — Krasnoyarsk Science Center of the Siberian Branch of the Russian Academy of Sciences; V.F. Voyno-Yasenetsky Krasnoyarsk State Medical UniversityRussian Federation

2023

12072023

28654855485

2023

Гоголашвили Н.Г.

Gogolashvili N.G.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://russjcardiol.elpub.ru/jour/article/view/5485

С учетом высокой заболеваемости и смертности, вызванной сердечно-сосудистыми заболеваниями в Российской Федерации, определение подходов к лекарственной терапии, способствующей снижению частоты развития осложнений и улучшению прогноза заболевания, приобретает все больше значения. Высокоинтенсивная статинотерапия — неотъемлемая часть терапии пациентов высокого и очень высокого сердечно-сосудистого риска, в то же время существует достаточно обширная когорта пациентов, которым оправдано назначение статинов в режиме умеренной интенсивности. В статье обсуждаются результаты исследования липидного профиля, клинические исходы, а также плейотропный эффект статинов, в частности, аторвастатина в режиме умеренной интенсивности.

High rates of cardiovascular (CV) morbidity and mortality dictates the need to determine approaches to therapy that would reduce complications rate and improve patient’s prognosis. High-intensity statin therapy is an integral part of the treatment of patients with high and very high cardiovascular risk. At the same time, there is a large cohort of patients who would benefit from moderate intensity statin therapy. In the present article we have summarized available data on hypolipidemic effects, pleiotropic effects and role of moderate intensity statin therapy, atorvastatin particularly, in reding the risk of major adverse cardiac events.

статинотерапиялипидный профильплейотропный эффект

statin therapylipid profilepleiotropic effects

References1

Healthcare in Russia 2019. Statistical Book. Moscow: Rosstat, 2019. p. 170. (In Russ.) Здравоохранение в России 2019. Статистический сборник. М.: Росстат, 2019. c. 200. ISBN: 978-5-89476-470-2.

Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-337. doi:10.1093/eurheartj/ehab484.

Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-81. doi:10.1016/S0140-6736(10)61350-5.

Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012:380(9841):581-90. doi:10.1016/S0140-6736(12)60367-5.

Fulcher J, O’Connell R, Voysey M, et al. Efficacy and safety of LDL lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397-405. doi:10.1016/S0140-6736(14)61368-4.

Gencer B, Marston NA, Im K, et al. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2020;396(10263):1637-43. doi:10.1016/S0140-6736(20)32332-1.

Сергиенко И. В., Прус Ю. А. Статины — длительность приема и снижение сердечно-сосудистого риска. РМЖ. 2021;1:25-8.

Sergienko IV, Prus YuA. Statins: treatment duration and cardiovascular risk reduction. RMJ. 2021;1:25-8. (In Russ.)

Поликарпов Л. С., Хамнагадаев И. И., Прахин Е. И. и др. Питание и особенности развития атеросклероза у детей и взрослых жителей Севера. Бюллетень Сибирского отделения Российской академии медицинских наук. 2010;30(6):129-35.

Polikarpov LS, Khamnagadaev II, Prakhin EI, et al. Nutrition and the peculiarities of atherosclerosis development in children and adults of the North. The Bulletin of the Siberian Branch of the Russian Academy of Medical Sciences. 2010;30(6):129-35. (In Russ.)

Гоголашвили Н. Г., Яскевич Р. А. Эффективность гиполипидемической терапии на амбулаторном этапе у пациентов с ишемической болезнью сердца, проживающих в крупном промышленном центре Восточной Сибири. Кардиоваскулярная терапия и профилактика. 2021;20(8):3135. doi:10.15829/1728-8800-2021-3135.

Gogolashvili NG, Yaskevich RA. Effectiveness of lipid lowering therapy in outpatients with coronary artery disease living in a large industrial center of Eastern Siberia. Cardiovascular Therapy and Prevention. 2021;20(8):3135. (In Russ.) doi:10.15829/1728-8800-2021-3135.

Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-88. doi:10.1093/eurheartj/ehz455.

Кухарчук В. В., Ежов М. В., Сергиенко И. В. и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VII пересмотр. Атеросклероз и дислипидемии. 2020;1(38):7-40.

Kukharchuk VV, Ezhov MV, Sergienko IV, et al. Diagnostics and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis. Russian recommendations, VII revision. Atherosclerosis and dyslipidemia. 2020;1(38):7-40. (In Russ.)

Mangione CM, Barry MJ, Nicholson WK et al. US Preventive Services Task Force; Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;328(8):746-53. doi:10.1001/jama.2022.13044.

Ежов М. В., Кухарчук В. В., Сергиенко И. В. и др. Нарушения липидного обмена. Клинические рекомендации 2023. Российский кардиологический журнал. 2023;28(6):5471. doi:10.15829/1560-4071-2023-5471. EDN YVZOWJ.

Yezhov MV, Kukharchuk VV, Sergienko IV, et al. Disorders of lipid metabolism. Clinical Guidelines 2023. Russian Journal of Cardiology. 2023;28(6):5471. (In Russ.) doi:10.15829/1560-4071-2023-5471. EDN YVZOWJ.

Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesteroleamia by atorvastatin, a new HMG-Ko-A reductase inhibitor. Arteriosclerosis Thromb Vascular Biology 1995;15:678-82. doi:10.1161/01.ATV.15.5.678.

Karalis DG, Ross AM, Vacari RM, et al. Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease. Am J Cardiol. 2002;89(6):667-71. doi:10.1016/S0002-9149(01)02337-2.

Clearfield MB, Amerena J, Bassand JP, et al. Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia — Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR). Trials. 2006;7:35. doi:10.1186/1745-6215-7-35.

McKenney JM, Jones PH, Adamczyk MA, et al. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin. 2003;19:689-98. doi:10.1185/030079903125002405.

Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326(7404):1423. doi:10.1136/bmj.326.7404.1423.

Weng TC, Yang YH, Lin SJ, Tai SH. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther. 2010;35(2):139-51. doi:10.1111/j.1365-2710.2009.01085.x.

Adams SP, Tsang M, Wright JM. Lipid-lowering efficacy of atorvastatin. Cochrane Database Syst Rev. 2015;(3):CD008226. doi:10.1002/14651858.CD008226.pub3.

Hodkinson A, Tsimpida D, Kontopantelis E, et al. Comparative effectiveness of statins on non-high density lipoprotein cholesterol in people with diabetes and at risk of cardiovascular disease: systematic review and network meta-analysis. BMJ. 2022;376:e067731. doi:10.1136/bmj-2021-067731.

Fujita M, Morimoto T, Ikemoto M, et al. Dose-dependency in pleiotropic effects of atorvastatin. Int J Angiol. 2007;16(3):89-91.

Bonnet J, McPherson R, Tedgui A, et al. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative AtorvastatinPleiotropic effects) study. Clin Ther. 2008;30(12):2298-313. doi:10.1016/j.clinthera.2008.12.023.

Grigoropoulou P, Tentolouris A, Eleftheriadou I, et al. Effect of 12-month intervention with low-dose atorvastatin on pulse wave velocity in subjects with type 2 diabetes and dyslipidaemia. Diab Vasc Dis Res. 2019;16(1):38-46. doi:10.1177/1479164118805320.

Liu Z, Joerg H, Hao H, et al. Efficacy of High-Intensity Atorvastatin for Asian Patients Undergoing Percutaneous Coronary Intervention. Ann Pharmacother. 2016;50(9):725-33. doi:10.1177/1060028016654722.

Liu Z, Xu Y, Hao H, et al. Efficacy of high intensity atorvastatin versus moderate intensity atorvastatin for acute coronary syndrome patients with diabetes mellitus. Int J Cardiol. 2016;222:22-6. doi:10.1016/j.ijcard.2016.07.140.

Gavazzoni M, Gorga E, Derosa G, et al. High-dose atorvastatin versus moderate dose on early vascular protection after ST-elevation myocardial infarction. Drug Des Devel Ther. 2017;11:3425-34. doi:10.2147/DDDT.S135173.

Sahebkar A, Pecin I, Tedeschi-Reiner E, et al. Effects of statin therapy on augmentation index as a measure of arterial stiffness: a systematic review and meta-analysis. Int J Cardiol. 2016;212:160-8. doi:10.1016/j.ijcard.2016.03.010.

Upala S, Wirunsawanya K, Jaruvongvanich V, Sanguankeo A. Effects of statin therapy on arterial stiffness: A systematic review and meta-analysis of randomized controlled trial. Int J Cardiol. 2017;227:338-41. doi:10.1016/j.ijcard.2016.11.073.

Alidadi M, Montecucco F, Jamialahmadi T, et al. Beneficial Effect of Statin Therapy on Arterial Stiffness. Biomed Res Int. 2021;2021:5548310. doi:10.1155/2021/5548310.

Nissen S, Tuzcu M, Schoenhagen P, et al. REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. JAMA. 2004;291(9):1071-80. doi:10.1001/jama.291.9.1071.

Nicholls SJ, Ballantyne СМ, Barter PhJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365:2078-87. doi:10.1056/NEJMoa1110874.

Tang X, Yang Y, Luo S, et al. The effect of statin therapy on plaque regression following acute coronary syndrome: a meta-analysis of prospective trials. Coron Artery Dis. 2016;27(8):636-49. doi:10.1097/MCA.0000000000000403.

Okazaki S, Yokoyama T, Miyauchi K, et al. Early Statin Treatment in Patients With Acute Coronary Syndrome. Demonstration of the Beneficial Effect on Atherosclerotic Lesions by Serial Volumetric Intravascular Ultrasound Analysis During Half a Year After Coronary Event: The ESTABLISH Study. Circulation. 2004;110:1061-8. doi:10.1161/01.CIR.0000140261.58966.A4.

Matsushita K, Hibi K, Komura N, et al. Effects of 4 Statins on Regression of Coronary Plaque in Acute Coronary Syndrome. Circ J. 2016;80(7):1634-43. doi:10.1253/circj.CJ-15-1379.

Komukai K, Kubo T, Kitabata H, et al. Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: the EASY-FIT study. J Am Coll Cardiol. 2014;64(21):2207-17. doi:10.1016/j.jacc.2014.08.045.

Ozaki Y, Garcia-Garcia HM, Beyene SS, et al. Effect of Statin Therapy on Fibrous Cap Thickness in Coronary Plaque on Optical Coherence Tomography — Review and Meta-Analysis. Circ J. 2019;83(7):1480-8. doi:10.1253/circj.CJ-18-1376.

DiNicolantonio JJ, Lavie CJ, Serebruany VL, O’Keefe JH. Statin wars: the heavyweight match — atorvastatin versus rosuvastatin for the treatment of atherosclerosis, heart failure, and chronic kidney disease. Postgrad Med. 2013;125(1):7-16. doi:10.3810/pgm.2013.01.2620.

Гоголашвили Н. Г. Аторвастатин — 20 лет в борьбе за жизнь. Российский кардиологический журнал. 2018;(2):134-49. doi:10.15829/1560-4071-2018-2-134-149.

Gogolashvili NG. Atorvastatin — 20 years in the struggle for life. Russian Journal of Cardiology. 2018;(2):134-49. (In Russ.) doi:10.15829/1560-4071-2018-2-134-149.

Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711-8. doi:10.1001/jama.285.13.1711.

LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425-35. doi:10.1056/NEJMoa050461.

Amarenco P, Bogousslavsky J, Callahan A 3rd, et al.; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549-59. doi:10.1056/NEJMoa061894.

Гоголашвили Н. Г. Статины и чрескожные коронарные вмешательства. Фокус на аторвастатин. Рациональная Фармакотерапия в Кардиологии. 2014;10(4):438-43.

Gogolashvili NG. Statins and percutaneous coronary intervention. Focus on atorvastatin. Rational Pharmacotherapy in Cardiology. 2014;10(4):438-43. (In Russ.)

Koren MJ, Hunninghake DB. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics. The ALLIANCE study. J Am Coll Cardiol. 2004;44:1772-9. doi:10.1016/j.jacc.2004.07.053.

Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364 685-96. doi:10.1016/S0140-6736(04)16895-5.

Colhoun HM, Betteridge DJ, Durrington PN, et al. CARDS Investigators. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis. 2009;54(5):810-9. doi:10.1053/j.ajkd.2009.03.022.

Sever PS, Dahlof B, Poulter NR, et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. J Hypertens. 2001;6:1139-47. doi:10.1097/00004872-200106000-00020.

Sever PS, Dahlöf B, Poulter N, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial — Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-58. doi:10.1016/S0140-6736(03)12948-0.

Sever PS, Poulter NR, Dahlof B, et al. Different Time Course for Prevention of Coronary and Stroke Events by Atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial — Lipid-Lowering Arm (ASCOT-LLA). Am J Cardiol. 2005;96:39F-44F. doi:10.1016/j.amjcard.2005.06.025.

Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895-906. doi:10.1016/S0140-6736(05)67185-1.

Sever P, Dahlof B, Poulter N, et al. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J. 2006;24:2982-8. doi:10.1093/eurheartj/ehl403.

Sever PS, Poulter NR, Dahlof B, et al. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension. J Hypertens. 2009;27(5):947-54. doi:10.1097/HJH.0b013e328326cb1a.

Gupta A, Mackay J, Whitehouse A, et al. Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial. Lancet. 2018;392(10153):1127-37. doi:10.1016/S0140-6736(18)31776-8.

Newman C, Tsai J, Szarek M, et al. Comparative Safety of Atorvasatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14236 patients. Am J Cardiology. 2006;97:61-7. doi:10.1016/j.amjcard.2005.07.108.

Yebyo HG, Aschmann HE, Kaufmann M, Puhan MA. Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. Am Heart J. 2019;210:18-28. doi:10.1016/j.ahj.2018.12.007.

Herrett E, Williamson E, Brack K, et al. Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials. BMJ. 2021;372:n135. doi:10.1136/bmj.n135.

Ko MJ, Jo AJ, Kim YJ, et al. Time- and Dose‐Dependent Association of Statin Use With risk of Clinically Relevant New‐Onset Diabetes Mellitus in Primary Prevention: A Nationwide Observational Cohort Study. J Am Heart Assoc. 2019;8:e011320.

Chow CK, Meng Q. Polypills for primary prevention of cardiovascular disease. Nat Rev Cardiol. 2019;16(10):602-11. doi:10.1038/s41569-019-0209-y.

Castellano JM, Sanz G, Penalvo JL, et al. A polypill strategy to improve adherence:results from the FOCUS project. J Am Coll Cardiol. 2014;64:2071-82. doi:10.1016/j.jacc.2014.08.021.

Patel A, Cass A, Peiris D, et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Eur J Prev Cardiol. 2015;22:920-30. doi:10.1177/2047487314530382.

Selak V, Elley CR, Bullen C, et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease:randomised controlled trial in primary care. BMJ. 2014;348:g3318. doi:10.1136/bmj.g3318.

Joseph P, Roshandel G, Gao P, et al. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet. 2021;398:1133-46. doi:10.1016/S0140-6736(21)01827-4.

Castellano JM, Pocock SJ, Bhatt DL, et al. Polypill Strategy in Secondary Cardiovascular Prevention. N Engl J Med. 2022;387(11):967-77. doi:10.1056/NEJMoa2208275.

Mohamed MG, Osman M, Kheiri B, et al. Polypill for cardiovascular disease prevention: Systematic review and meta-analysis of randomized controlled trials. Int J Cardiol. 2022;360:91-8. doi:10.1016/j.ijcard.2022.04.085.

Borghi C, Fogacci F, Agnoletti D, Cicero AFG. Hypertension and Dyslipidemia Combined Therapeutic Approaches. High Blood Press Cardiovasc Prev. 2022;29(3):221-30. doi:10.1007/s40292-022-00507-8.

Dézsi CA. Treatment with triple combination of atorvastatin, perindopril, and amlodipine in patients with stable coronary artery disease: A subgroup analysis from the PAPA-CAD study. J Int Med Res. 2018;46(5):1902-9. doi:10.1177/0300060518760158.

Simon A, Dézsi CA. Treatment of hypertensive and hypercholesterolaemic patients with the triple fixed combination of atorvastatin, perindopril and amlodipine: the results of the CORAL Study. Adv Ther. 2019;36(8):2010-20. doi:10.1007/s12325-019-01002-8.

The authors declare that there are no conflicts of interest present.